The Presage ST2 Assay measures the level of ST2 in blood and is used for demonstrating the prognosis of patients diagnosed with chronic heart failure.
Critical Diagnostics president James Snider said through the use of the Presage ST2 Assay, clinicians can assess patient prognosis with the hope of being able to better personalize care.
Duke University School of Medicine Cardiology division associate professor Michael Felker said in the future, there is hope that a better understanding of prognosis using markers like ST2 can help then guide therapy and improve outcomes in heart failure patients.
